A Phase 3 interventional study of Telaprevir and Ribavirin in Hepatitis C, sponsored by Vertex Pharmaceuticals Incorporated. Terminated at 59 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-03-17.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing telaprevir in Hepatitis C — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C.
Among the 39 studies testing telaprevir in Hepatitis C, this one is the 8th largest by enrollment, is one of 4 that started in 2011, is one of 13 in phase 3, and was the 21st registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 39 studies testing telaprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 9 · Phase 3 13 · Phase 4 5
First in 2005; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 185 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 30 across the 39 interventional studies. Of the 37 that completed or were terminated, 20 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 39 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
19 studies in Hepatitis C by Vertex Pharmaceuticals Incorporated: none open now, none under way, none of them phase 3. Of 19 finished, 9 (47%) have results posted.
Among the 19 studies in Hepatitis C by Vertex Pharmaceuticals Incorporated, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2011, is one of 3 in phase 3, and was the 15th registered.
Vertex Pharmaceuticals Incorporated’s Hepatitis C studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing telaprevir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Vertex Pharmaceuticals Incorporated’s 19 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to treat human immunodeficiency virus (HIV) and Hepatitis C Virus (HCV) co-infected subjects with telaprevir, pegylated interferon alfa-2a (Peg-IFN-alfa-2a), and ribavirin (RBV) to achieve undetectable hepatitis C virus ribonucleic acid (HCV RNA) 12 weeks after the last planned dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants should be taking 1 of the following permissible highly active antiretroviral therapy (HAART) regimens for HIV continuously for 12 weeks prior to screening:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who were receiving atazanavir/ritonavir (ATV/r) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
Drug: Telaprevir · Drug: Ribavirin · Biological: Pegylated Interferon Alfa-2a · Drug: Highly Active Antiretroviral Therapy (HAART)
Participants who were receiving efavirenz (EFV) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet three times a day for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
Drug: Telaprevir · Drug: Ribavirin · Biological: Pegylated Interferon Alfa-2a · Drug: Highly Active Antiretroviral Therapy (HAART)
Participants who were receiving raltegravir (RAL) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
Drug: Telaprevir · Drug: Ribavirin · Biological: Pegylated Interferon Alfa-2a · Drug: Highly Active Antiretroviral Therapy (HAART)
Tablet
Also known as: VX-950
Tablet
Also known as: Copegus®, RBV
Subcutaneous Injection
Also known as: Pegasys®, Peg-IFN-Alfa-2a
Atazanavir/ritonavir (ATV/r) based HAART, Efavirenz (EFV) based HAART, or Raltegravir (RAL) based HAART, as per standard practice. HAART medications were not considered study drugs.
Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)
SVR 12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (\<lower limit of quantification) at 12 weeks after last planned dose of study drug. The plasma hepatitis C virus ribonucleic acid (HCV RNA) level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL).
Time frame: 12 weeks after last planned dose of study drug (up to Week 60)
Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR 24)
SVR 24 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (\<lower limit of quantification) at 24 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL).
Time frame: 24 weeks after last planned dose of study drug (up to Week 72)
Percentage of Participants With Rapid Viral Response (RVR)
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. RVR was defined as undetectable HCV RNA (\<lower limit of quantification) 4 weeks after the start of study treatment.
Time frame: Week 4
Percentage of Participants With Extended Rapid Viral Response (eRVR)
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. eRVR was defined as undetectable HCV RNA (\<lower limit of quantification) at both 4 weeks and 12 weeks after the start of study treatment.
Time frame: Week 4 and Week 12
Percentage of Participants With Undetectable HCV RNA at End of Treatment (EOT)
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. Percentage of participants with undetectable HCV RNA (\<lower limit of quantification) at EOT (up to Week 48) are reported. Data for this outcome was not planned to be reported by prior response.
Time frame: EOT (up to Week 48)
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.
Time frame: Up to Week 52
Maximum (Cmax), Minimum (Cmin), and Average Plasma Concentration (Cavg)
Cmax, Cmin, and Cavg were reported for atazanavir (ATV), efavirenz (EFV), raltegravir (RAL), and telaprevir.
Time frame: Day -14 to Day -1 and Week 1 for ATV, EFV, and RAL; Week 1 for telaprevir
Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region
Sequence analysis of the HCV NS3-4A region was performed to monitor telaprevir-resistant variants. HCV RNA was isolated from the plasma, amplified by reverse transcription-polymerase chain reaction (RT-PCR), and sequenced (sequencing assay limit of detection HCV RNA \>=1000 IU/mL). Results of this outcome measure were to be reported for overall participants instead of by HAART treatment.
Time frame: Baseline, follow-up (Week 96)
Study included Treatment-Naïve (no prior hepatitis C virus \[HCV\] therapy); Prior Relapser (prior HCV treatment with pegylated interferon alfa/ribavirin \[Peg-IFN/RBV\] and experienced viral relapse); and Prior Null/Partial Responder (prior HCV treatment with Peg-IFN/RBV and had null/partial response) participants.
| Milestone | T/PR + HAART Regimen (ATV/r-Based) | T/PR + HAART Regimen (EFV-Based) | T/PR + HAART Regimen (RAL-Based) |
|---|---|---|---|
| Started | 55 | 69 | 61 |
| Treated | 54 | 69 | 59 |
| Completed | 46 | 52 | 45 |
| Not completed | 9 | 17 | 16 |
| Withdrew: No study medication | 1 | 0 | 2 |
| Withdrew: Adverse event | 1 | 2 | 0 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 5 | 3 |
| Withdrew: Withdrawal of consent | 3 | 7 | 7 |
| Withdrew: Study terminated by sponsor | 1 | 3 | 3 |
| Withdrew: Other | 1 | 0 | 0 |
SVR 12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (\<lower limit of quantification) at 12 weeks after last planned dose of study drug. The plasma hepatitis C virus ribonucleic acid (HCV RNA) level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL).
| percentage of participants | T/PR + HAART Regimen (ATV/r-Based) | T/PR + HAART Regimen (EFV-Based) | T/PR + HAART Regimen (RAL-Based) |
|---|---|---|---|
| Treatment Naïve (n= 24, 39, 31) | 66.7 | 59.0 | 61.3 |
| Prior Relapser (n=8, 11, 4) | 75.0 | 54.5 | 100 |
| Prior Null Responder (n= 15, 11, 15) | 40 | 36.4 | 40 |
| Prior Partial Responder (n= 7, 8, 9) | 14.3 | 87.5 | 55.6 |
| Total (n= 54, 69, 59) | 53.7 | 58.0 | 57.6 |
SVR 24 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (\<lower limit of quantification) at 24 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL).
| percentage of participants | T/PR + HAART Regimen (ATV/r-Based) | T/PR + HAART Regimen (EFV-Based) | T/PR + HAART Regimen (RAL-Based) |
|---|---|---|---|
| Treatment Naïve (n= 23, 38, 29) | 65.2 | 57.9 | 51.7 |
| Prior Relapser (n=8, 11, 4) | 75.0 | 54.5 | 100 |
| Prior Null Responder (n= 15, 9, 14) | 33.3 | 22.2 | 35.7 |
| Prior Partial Responder (n= 7, 8, 9) | 14.3 | 75.0 | 55.6 |
| Total (n= 53, 66, 56) | 50.9 | 54.5 | 51.8 |
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. RVR was defined as undetectable HCV RNA (\<lower limit of quantification) 4 weeks after the start of study treatment.
| percentage of participants | T/PR + HAART Regimen (ATV/r-Based) | T/PR + HAART Regimen (EFV-Based) | T/PR + HAART Regimen (RAL-Based) |
|---|---|---|---|
| Treatment Naïve (n= 24, 39, 31) | 50.0 | 53.8 | 74.2 |
| Prior Relapser (n=8, 11, 4) | 62.5 | 72.7 | 100 |
| Prior Null Responder (n= 15, 11, 15) | 26.7 | 54.5 | 53.3 |
| Prior Partial Responder (n= 7, 8, 9) | 42.9 | 50.0 | 44.4 |
| Total (n= 54, 69, 59) | 44.4 | 56.5 | 66.1 |
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. eRVR was defined as undetectable HCV RNA (\<lower limit of quantification) at both 4 weeks and 12 weeks after the start of study treatment.
| percentage of participants | T/PR + HAART Regimen (ATV/r-Based) | T/PR + HAART Regimen (EFV-Based) | T/PR + HAART Regimen (RAL-Based) |
|---|---|---|---|
| Treatment Naïve (n= 24, 39, 31) | 50.0 | 53.8 | 61.3 |
| Prior Relapser (n=8, 11, 4) | 62.5 | 72.7 | 100 |
| Prior Null Responder (n= 15, 11, 15) | 26.7 | 54.5 | 53.3 |
| Prior Partial Responder (n= 7, 8, 9) | 14.3 | 50.0 | 44.4 |
| Total (n= 54, 69, 59) | 40.7 | 56.5 | 59.3 |
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. Percentage of participants with undetectable HCV RNA (\<lower limit of quantification) at EOT (up to Week 48) are reported. Data for this outcome was not planned to be reported by prior response.
| percentage of participants | T/PR + HAART Regimen (ATV/r-Based) | T/PR + HAART Regimen (EFV-Based) | T/PR + HAART Regimen (RAL-Based) |
|---|---|---|---|
| Percentage of Participants With Undetectable HCV RNA at End of Treatment (EOT) | 55.6 | 63.8 | 61.0 |
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.
| percentage of participants | T/PR + HAART Regimen (ATV/r-Based) | T/PR + HAART Regimen (EFV-Based) | T/PR + HAART Regimen (RAL-Based) |
|---|---|---|---|
| AEs | 100 | 95.7 | 94.9 |
| SAEs | 13.0 | 11.6 | 15.3 |
Cmax, Cmin, and Cavg were reported for atazanavir (ATV), efavirenz (EFV), raltegravir (RAL), and telaprevir.
| nanogram per milliliter (ng/mL) | T/PR + HAART Regimen (ATV/r-Based) | T/PR + HAART Regimen (EFV-Based) | T/PR + HAART Regimen (RAL-Based) |
|---|---|---|---|
| ATV: Day -14 to Day -1, Cmax(n=46, 0, 0) | 2870 ± 1580 | NA ± NA | NA ± NA |
| ATV: Day -14 to Day -1, Cmin(n=46, 0, 0) | 991 ± 635 | NA ± NA | NA ± NA |
| ATV: Day -14 to Day -1, Cavg(n=41, 0, 0) | 1100 ± 647 | NA ± NA | NA ± NA |
| ATV: Week 1, Cmax (n=42, 0, 0) | 2820 ± 1570 | NA ± NA | NA ± NA |
| ATV: Week 1, Cmin (n=42, 0, 0) | 1280 ± 636 | NA ± NA | NA ± NA |
| ATV: Week 1, Cavg (n=30, 0, 0) | 1320 ± 685 | NA ± NA | NA ± NA |
| EFV: Day -14 to Day -1, Cmax(n=0, 60, 0) | NA ± NA | 3800 ± 2600 | NA ± NA |
| EFV: Day -14 to Day -1, Cmin(n=0, 60, 0) | NA ± NA | 2560 ± 1900 | NA ± NA |
| EFV: Day -14 to Day -1, Cavg(n=0, 51, 0) | NA ± NA | 2150 ± 1680 | NA ± NA |
| EFV: Week 1, Cmax (n=0, 51, 0) | NA ± NA | 3340 ± 2450 | NA ± NA |
| EFV: Week 1, Cmin (n=0, 51, 0) | NA ± NA | 2290 ± 1880 | NA ± NA |
| EFV: Week 1, Cavg (n=0, 47, 0) | NA ± NA | 1920 ± 1400 | NA ± NA |
| RAL: Day -14 to Day -1, Cmax(n=0, 0, 52) | NA ± NA | NA ± NA | 1900 ± 1880 |
| RAL: Day -14 to Day -1, Cmin(n=0, 0, 52) | NA ± NA | NA ± NA | 196 ± 198 |
| RAL: Day -14 to Day -1, Cavg(n=0, 0, 35) | NA ± NA | NA ± NA | 483 ± 429 |
| RAL: Week 1, Cmax (n=0, 0, 49) | NA ± NA | NA ± NA | 2320 ± 1970 |
| RAL: Week 1, Cmin (n=0, 0, 49) | NA ± NA | NA ± NA | 281 ± 435 |
| RAL: Week 1, Cavg (n=0, 0, 34) | NA ± NA | NA ± NA | 643 ± 539 |
| Telaprevir: Week 1, Cmax(n=49, 59, 54) | 3160 ± 1180 | 3780 ± 1670 | 3470 ± 868 |
| Telaprevir: Week 1, Cmin(n=49, 59, 54) | 1650 ± 863 | 1750 ± 961 | 1840 ± 741 |
| Telaprevir: Week 1, Cavg(n=30, 32, 26) | 2320 ± 907 | 2430 ± 1290 | 2520 ± 643 |
Sequence analysis of the HCV NS3-4A region was performed to monitor telaprevir-resistant variants. HCV RNA was isolated from the plasma, amplified by reverse transcription-polymerase chain reaction (RT-PCR), and sequenced (sequencing assay limit of detection HCV RNA \>=1000 IU/mL). Results of this outcome measure were to be reported for overall participants instead of by HAART treatment.
| participants | T/PR + HAART Regimen |
|---|---|
| Baseline (n = 180) | 2 |
| Follow-up (n = 26) | 11 |
Collected over Baseline up to Week 52. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T/PR + HAART Regimen (ATV/r-Based) | — | 7/54 (13%) | 54/54 (100%) |
| T/PR + HAART Regimen (EFV-Based) | — | 8/69 (11.6%) | 66/69 (95.7%) |
| T/PR + HAART Regimen (RAL-Based) | — | 9/59 (15.3%) | 56/59 (94.9%) |
| Event | T/PR + HAART Regimen (ATV/r-Based) | T/PR + HAART Regimen (EFV-Based) | T/PR + HAART Regimen (RAL-Based) |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/54 | 3/69 | 4/59 |
| NeutropeniaBlood and lymphatic system disorders | 1/54 | 1/69 | 1/59 |
| LeukocytosisBlood and lymphatic system disorders | 1/54 | 0/69 | 0/59 |
| VomitingGastrointestinal disorders | 1/54 | 0/69 | 0/59 |
| Escherichia urinary tract infectionInfections and infestations | 1/54 | 0/69 | 0/59 |
| Psoas abscessInfections and infestations | 1/54 | 0/69 | 0/59 |
| Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders | 1/54 | 0/69 | 0/59 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/54 | 0/69 | 0/59 |
| Non-cardiac chest painGeneral disorders | 1/54 | 0/69 | 0/59 |
| Flank painMusculoskeletal and connective tissue disorders | 1/54 | 0/69 | 0/59 |
| Event | T/PR + HAART Regimen (ATV/r-Based) | T/PR + HAART Regimen (EFV-Based) | T/PR + HAART Regimen (RAL-Based) |
|---|---|---|---|
| FatigueGeneral disorders | 26/54 | 36/69 | 30/59 |
| NauseaGastrointestinal disorders | 23/54 | 22/69 | 19/59 |
| PruritusSkin and subcutaneous tissue disorders | 22/54 | 21/69 | 18/59 |
| HeadacheNervous system disorders | 15/54 | 17/69 | 20/59 |
| DiarrhoeaGastrointestinal disorders | 13/54 | 21/69 | 6/59 |
| AnaemiaBlood and lymphatic system disorders | 15/54 | 21/69 | 16/59 |
| RashSkin and subcutaneous tissue disorders | 16/54 | 20/69 | 11/59 |
| InsomniaPsychiatric disorders | 9/54 | 14/69 | 14/59 |
| NeutropeniaBlood and lymphatic system disorders | 10/54 | 15/69 | 4/59 |
| VomitingGastrointestinal disorders | 10/54 | 11/69 | 11/59 |
The Full Analysis Set (FAS), included all randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | T/PR + HAART Regimen (ATV/r-Based) | T/PR + HAART Regimen (EFV-Based) | T/PR + HAART Regimen (RAL-Based) | Total |
|---|---|---|---|---|
| Mean | 50.4 ± 8.81 | 49.6 ± 8.84 | 48.4 ± 9.58 | 49.5 ± 9.06 |
| Sex: Female, Male(Participants) | T/PR + HAART Regimen (ATV/r-Based) | T/PR + HAART Regimen (EFV-Based) | T/PR + HAART Regimen (RAL-Based) | Total |
|---|---|---|---|---|
| Female | 6 | 9 | 15 | 30 |
| Male | 48 | 60 | 44 | 152 |
The record gives a start of Dec 2011, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Telaprevir · Ribavirin · Peginterferon alfa-2a
Vertex Pharmaceuticals Incorporated →